Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma

Flood-Knapik, K. E.; Durham, Amy C.; Gregor, Thomas P.; Sánchez, Melissa D.; Durney, M. E.; Sørenmo, Karin U.

doi:10.1111/j.1476-5829.2011.00317.x

Cited by 102 publications

(199 citation statements)

References 41 publications

Supporting

Mentioning

176

Contrasting

Unclassified

Order By: Relevance

“…T zone lymphoma is generally characterized by a prolonged clinical course, and there are data to support the idea that CHOP chemotherapy is no more effective than treatment with prednisone and chlorambucil 28. CD4+/CD45+ T‐cell lymphoma is aggressive, and although multi drug treatment extends survival, the majority of patients die of their disease by 300 days.…”

Section: Discussionmentioning

confidence: 99%

Flow Cytometric Characterization and Clinical Outcome of CD4+ T‐Cell Lymphoma in Dogs: 67 Cases

Avery

Burton

Bromberek

et al. 2014

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundCanine T‐cell lymphoma (TCL) is conventionally considered an aggressive disease, but some forms are histologically and clinically indolent. CD4 TCL is reported to be the most common subtype of TCL. We assessed flow cytometric characteristics, histologic features when available, and clinical outcomes of CD4+ TCL to determine if flow cytometry can be used to subclassify this group of lymphomas.ObjectiveTo test the hypothesis that canine CD4+ T‐cell lymphoma (TCL) is a homogeneous group of lymphomas with an aggressive clinical course.AnimalsSixty‐seven dogs diagnosed with CD4+ TCL by flow cytometry and treated at 1 of 3 oncology referral clinics.MethodsRetrospective multivariable analysis of outcome in canine CD4+ TCL including patient characteristics, treatment, and flow cytometric features.ResultsThe majority of CD4+ TCL were CD45+, expressed low class II MHC, and exhibited an aggressive clinical course independent of treatment regimen (median survival, 159 days). Histologically, CD4+ TCL were classified as lymphoblastic or peripheral T cell. Size of the neoplastic lymphocytes had a modest effect on both PFI and survival in this group. A small number of CD4+ TCL were CD45− and class II MHC high, and exhibited an apparently more indolent clinical course (median survival not yet reached).Conclusions and Clinical ImportanceAlthough the majority of CD4+ TCL in dogs had uniform clinical and flow cytometric features and an aggressive clinical course, a subset had a unique immunophenotype that predicts significantly longer survival. This finding strengthens the utility of flow cytometry to aid in the stratification of canine lymphoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Flow Cytometric Characterization and Clinical Outcome of CD4+ T‐Cell Lymphoma in Dogs: 67 Cases

Avery

Burton

Bromberek

et al. 2014

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…Interestingly, in this study where 40% of the TCL dogs were WHO substage b, the median OS, when defined as time from diagnosis to death, was 602 days, with 2 dogs (1 Stage 3A, 1 Stage 5b) still alive at manuscript preparation. Factors that may have positively influenced the survival of the dogs in this study include the higher doses of HDC and TBI used in the pre‐PBHCT conditioning regimen and the unknown number of dogs with low‐grade tumors27 because a LN biopsy was obtained in only 3 dogs (all 3 dogs were diagnosed with an aggressive T‐cell lymphoma called peripheral T‐cell lymphoma). In addition, because 87% of the dogs maintained a first remission (median, 3.7 months; range, 2–5.8 months) before transplantation, a positive selection bias in this population may have influenced our results.…”

Section: Discussionmentioning

confidence: 99%

Autologous Peripheral Blood Hematopoietic Cell Transplantation in Dogs with T‐Cell Lymphoma

Warry

Willcox

Suter

2014

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundPeripheral blood hematopoietic cell transplantation (PBHCT) is a feasible treatment option for dogs with B‐cell lymphoma.ObjectiveTo examine apheresis and PBHCT outcomes in dogs diagnosed with T‐cell lymphoma (TCL).AnimalsFifteen client‐owned dogs diagnosed with high‐grade TCL.MethodsAfter high‐dose cyclophosphamide and rhG‐colony‐stimulating (rhG‐CSF) factor treatment, peripheral blood mononuclear cells were collected using cell separators. The harvested cells then were infused after varying doses of total body irradiation (TBI). Postirradiation adverse effects were managed symptomatically and dogs were discharged upon evidence of hematopoietic engraftment.ResultsMore than 2 × 106 CD34+ cells/kg were harvested from 15/15 dogs. Thirteen of 15 (87%) dogs engrafted appropriately, whereas 2 (13%) of the dogs died in the hospital. One dog developed cutaneous B‐cell lymphoma 120 days post‐PBHCT. The median disease‐free interval and overall survival (OS) of the 13 dogs transplanted in first remission from the time of PBHCT were 184 and 240 days, respectively. Stage and substage of disease at diagnosis had no effect on OS. Two of 13 (15%) dogs were alive 741 and 772 days post‐PBHCT.Conclusions and Clinical Importance PBHCT may be considered as a treatment option for dogs with TCL.

show abstract

“…However, there are no studies with detailed analysis of P-gp expression in particular histological subtypes of lymphomas. Only Flood-Knapik et al (2013) investigated expression of this protein in canine indolent lymphomas classified according to WHO scheme, but they did not found its presence in any of the examined cases. Moreover, Lee et al (1996) also classified morphologically examined lymphomas, but they did not give any information regarding P-gp expression in particular subtypes of lymphoma.…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemical detection of P-glycoprotein in various subtypes of canine lymphomas

Sokołowska¹,

Urbańska²,

Gizinski³

et al. 2015

Polish Journal of Veterinary Sciences

View full text Add to dashboard Cite

Combination chemiotherapy is the current standard of care for dogs with lymphoma. Multidrug resistance is one of the most important factors contributing to the efficacy of chemiotherapy. The major protein responsible for this phenomenon is P-glycoprotein. Little is known about P-glycoprotein expression in particular subtypes of lymphomas. The aim of the study was evaluation of P-glycoprotein expression in various subtypes of canine lymphomas. Positive reaction with P-glycoprotein was found in 12/25 cases of various morphological subtypes of lymphomas, however, in 3/11 lymphomas the percentage of positively weakly stained cells was <10% and those tumors were also considered negative. Tumors with 10-50% P-glycoprotein positive cells were found in single cases of centroblastic and centroblastic-centrocytic tumors. In 5 lymphomas P-glycoprotein expression exceeded 50% of tumor cells. Those cases were found among centroblastic, centroblastic-centrocytic, lymphoblastic and Burkitt-like subtypes. Positive reaction was observed mainly in the cell cytoplasm, however, in some cases prominent perinuclear dot-like staining pattern was found. In 2 cases focal staining pattern comprised dominant type of immunolabelling. Among all lymphomas containing P-glycoprotein positive cells intensity of imunolabelling was assessed as weak (6/25), moderate (2/25) and strong (3/25). Our results indicate that P-glycoprotein expression is present in nearly one third of newly diagnosed canine lymphomas of different morphological subtypes including those most commonly occurring, such as cenroblastic lymphomas. Hence, determination of P-glycoprotein expression at the time of diagnosis could provide valuable information for the design of treatment protocols. Moreover, our results have shown that P-glycoprotein expression in canine tumors could be located in Golgi-zone.

show abstract

Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma

Cited by 102 publications

References 41 publications

Flow Cytometric Characterization and Clinical Outcome of CD4+ T‐Cell Lymphoma in Dogs: 67 Cases

Flow Cytometric Characterization and Clinical Outcome of CD4+ T‐Cell Lymphoma in Dogs: 67 Cases

Autologous Peripheral Blood Hematopoietic Cell Transplantation in Dogs with T‐Cell Lymphoma

Immunohistochemical detection of P-glycoprotein in various subtypes of canine lymphomas

Contact Info

Product

Resources

About